First Eagle Investment Management LLC Acquires 59,525 Shares of Enovis Co. (NYSE:ENOV)

First Eagle Investment Management LLC boosted its holdings in Enovis Co. (NYSE:ENOV) by 20.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 343,921 shares of the company’s stock after buying an additional 59,525 shares during the quarter. First Eagle Investment Management LLC’s holdings in Enovis were worth $15,091,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. UMB Bank n.a. increased its position in Enovis by 128.2% during the 4th quarter. UMB Bank n.a. now owns 778 shares of the company’s stock valued at $34,000 after purchasing an additional 437 shares during the period. Pinnacle Bancorp Inc. increased its position in Enovis by 54.5% during the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock valued at $37,000 after purchasing an additional 300 shares during the period. FMR LLC increased its position in Enovis by 20.5% during the 3rd quarter. FMR LLC now owns 2,840 shares of the company’s stock valued at $122,000 after purchasing an additional 484 shares during the period. XTX Topco Ltd acquired a new stake in Enovis during the 3rd quarter valued at approximately $217,000. Finally, Legacy Capital Wealth Partners LLC acquired a new stake in Enovis during the 4th quarter valued at approximately $228,000. Institutional investors own 98.45% of the company’s stock.

Enovis Stock Performance

Shares of ENOV stock opened at $37.01 on Friday. The company has a market cap of $2.11 billion, a price-to-earnings ratio of -16.90 and a beta of 2.05. Enovis Co. has a 52 week low of $35.14 and a 52 week high of $62.79. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The firm has a 50 day moving average of $43.32 and a 200-day moving average of $43.74.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.92 by $0.06. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company had revenue of $560.98 million during the quarter, compared to the consensus estimate of $555.14 million. On average, equities analysts forecast that Enovis Co. will post 2.79 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reduced their price objective on shares of Enovis from $65.00 to $64.00 and set a “buy” rating for the company in a research report on Thursday, February 27th.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.